You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFurosemide
Accession NumberDB00695  (APRD00608, DB07799)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]
Structure
Thumb
Synonyms
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
Frusemide
Furosemid
Furosemida
Furosemide
Furosemidu
Furosemidum
Lasix (tn)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-furosemideTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet20 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet40 mgOralAvanstra Inc2011-08-112014-08-21Canada
Bio-furosemideTablet20 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-furosemideTablet40 mgOralBiomed Pharma2003-04-11Not applicableCanada
Dom-furosemideTablet20 mgOralBiomed Pharma2003-10-142013-08-02Canada
Dom-furosemideTablet40 mgOralBiomed Pharma2003-10-142013-08-02Canada
FuosemideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralREMEDYREPACK INC.2013-05-23Not applicableUs
FurosemideInjection10 mg/mLIntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
FurosemideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc1981-10-19Not applicableUs
FurosemideTablet20 mg/1OralSandoz Inc1981-10-19Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2000-07-12Not applicableUs
FurosemideTablet80 mg/1OralA S Medication Solutions Llc1981-10-19Not applicableUs
FurosemideTablet40 mg/1OralCardinal Health1981-08-27Not applicableUs
FurosemideTablet40 mg/1OralWest Ward Pharmaceuticals Corp.1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralClinical Solutions Wholesale1983-11-10Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2010-07-13Not applicableUs
FurosemideTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc1981-10-19Not applicableUs
FurosemideTablet80 mg/1OralMajor Pharmaceuticals2008-03-26Not applicableUs
FurosemideTablet80 mgOralSanis Health Inc2010-06-15Not applicableCanada
FurosemideTablet40 mg/1OralCardinal Health2008-03-26Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
FurosemideTablet20 mg/1OralIVAX Pharmaceuticals, Inc.1983-11-30Not applicableUs
FurosemideTablet20 mg/1OralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
FurosemideTablet40 mg/1OralMylan Pharmaceuticals Inc.1981-08-27Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2013-11-19Not applicableUs
FurosemideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-30Not applicableUs
FurosemideTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-20Not applicableUs
FurosemideTablet40 mg/1OralSandoz Inc1981-10-19Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions Llc1981-10-19Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health1981-08-27Not applicableUs
FurosemideTablet20 mg/1OralWest Ward Pharmaceuticals Corp.1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralA S Medication Solutions1981-08-27Not applicableUs
FurosemideTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc1983-11-10Not applicableUs
FurosemideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2010-07-13Not applicableUs
FurosemideInjection10 mg/mLIntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
FurosemideTablet40 mg/1OralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousHospira, Inc.1982-05-28Not applicableUs
FurosemideTablet20 mg/1OralMylan Institutional Inc.1995-10-01Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2013-05-22Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health2010-10-12Not applicableUs
FurosemideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-30Not applicableUs
FurosemideTablet20 mg/1OralAvera Mc Kennan Hospital2015-06-09Not applicableUs
FurosemideTablet20 mg/1OralMajor Pharmaceuticals2008-03-26Not applicableUs
FurosemideTablet20 mgOralSanis Health Inc2010-06-15Not applicableCanada
FurosemideTablet40 mg/1OralA S Medication Solutions Llc1981-10-19Not applicableUs
FurosemideInjection20 mg/2mLIntramuscular; IntravenousMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-02-01Not applicableUs
FurosemideTablet40 mg/1OralWest Ward Pharmaceuticals Corp.1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2010-07-13Not applicableUs
FurosemideInjection10 mg/mLIntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
FurosemideTablet80 mg/1OralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
FurosemideTablet80 mg/1OralSandoz Inc1981-10-19Not applicableUs
FurosemideTablet40 mg/1OralMylan Institutional Inc.1995-10-01Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2013-05-23Not applicableUs
FurosemideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
FurosemideTablet40 mg/1OralCardinal Health2010-10-12Not applicableUs
FurosemideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1981-10-19Not applicableUs
FurosemideTablet40 mg/1OralMajor Pharmaceuticals2008-03-26Not applicableUs
FurosemideTablet40 mgOralSanis Health Inc2010-06-15Not applicableCanada
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2013-03-14Not applicableUs
FurosemideTablet40 mg/1OralIVAX Pharmaceuticals, Inc.1983-11-30Not applicableUs
FurosemideTablet40 mg/1OralContract Pharmacy Services Pa2010-04-12Not applicableUs
FurosemideTablet20 mg/1OralMylan Pharmaceuticals Inc.1981-08-27Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health2008-03-26Not applicableUs
FurosemideTablet20 mg/1OralWest Ward Pharmaceuticals Corp.1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-28Not applicableUs
FurosemideTablet20 mg/1OralClinical Solutions Wholesale1983-11-10Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2010-07-13Not applicableUs
Furosemide 20 TabTablet20 mgOralPro Doc Limitee1980-12-31Not applicableCanada
Furosemide 20mg TabletsTablet20 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Furosemide 40mgTablet40 mgOralPro Doc Limitee1977-12-31Not applicableCanada
Furosemide 40mg TabTablet40 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Furosemide 40mg TabletsTablet40 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Furosemide Inj 10mg/mlLiquid10 mgIntramuscular; IntravenousInternational Medication Systems Ltd.1979-12-311997-08-15Canada
Furosemide Inj USPLiquid10 mgIntramuscular; IntravenousSandoz Canada Incorporated1981-12-31Not applicableCanada
Furosemide InjectionLiquid10 mgIntramuscular; IntravenousOmega Laboratories Ltd2011-06-08Not applicableCanada
Furosemide Injection SdzSolution10 mgIntramuscular; IntravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Furosemide Injection USPSolution10 mgIntravenousHospira Healthcare Corporation1982-12-31Not applicableCanada
Furosemide Injection USPSolution10 mgIntramuscular; IntravenousTeligent Ou2013-08-22Not applicableCanada
Furosemide SpecialSolution10 mgIntravenousSandoz Canada Incorporated1991-12-31Not applicableCanada
Furosemide Special InjectionLiquid10 mgIntravenousOmega Laboratories Ltd2011-06-08Not applicableCanada
Furosemide Special SdzSolution10 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Furosemide-80 Tab 80mgTablet80 mgOralPro Doc Limitee1995-12-31Not applicableCanada
Furoside Tab 20mgTablet20 mgOralIcn Canada Ltd.1976-12-312005-04-26Canada
Furoside Tab 40mgTablet40 mgOralIcn Canada Ltd.1978-12-312005-04-26Canada
LasixTablet40 mg/1OralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
LasixTablet40 mg/1OralValidus Pharmaceuticals LLC1966-07-01Not applicableUs
LasixTablet80 mg/1OralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
LasixTablet80 mg/1OralValidus Pharmaceuticals LLC1978-04-24Not applicableUs
LasixTablet20 mgOralSanofi Aventis Canada Inc1997-04-212014-06-09Canada
LasixTablet20 mg/1OralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
LasixTablet20 mg/1OralValidus Pharmaceuticals LLC1974-05-07Not applicableUs
LasixTablet40 mgOralSanofi Aventis Canada Inc1997-04-212014-06-09Canada
Lasix - Tab 80mgTablet80 mgOralAventis Pharma Inc1997-08-202003-07-22Canada
Lasix 40mg TabletsTablet40 mgOralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada
Lasix 80mg TabletsTablet80 mgOralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Injection 10mg/mlLiquid10 mgIntramuscular; IntravenousHoechst Roussel Canada Inc.1994-12-312000-07-28Canada
Lasix Injection 10mg/ml - Im IVLiquid10 mgIntramuscular; IntravenousHoechst Marion Roussel Canada Inc.1998-11-122001-07-31Canada
Lasix Oral Soln 10mg/mlLiquid10 mgOralHoechst Canada Inc.1978-12-311997-08-05Canada
Lasix Oral Solution 10mg/mlSolution10 mgOralSanofi Aventis Canada Inc1996-12-04Not applicableCanada
Lasix Oral Solution 10mg/mlLiquid10 mgOralHoechst Roussel Canada Inc.1994-12-311998-08-12Canada
Lasix Parenteral InjLiquid20 mgIntramuscular; IntravenousHoechst Canada Inc.1968-12-311996-08-29Canada
Lasix Parenteral Injection 10mg/mlLiquid10 mgIntramuscular; IntravenousHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Lasix SpecialTablet500 mgOralSanofi Aventis Canada Inc1997-08-20Not applicableCanada
Lasix Special Inj 10mg/mlLiquid10 mgIntravenousHoechst Canada Inc.1976-12-311999-08-11Canada
Lasix Special Tab 500mgTablet500 mgOralHoechst Canada Inc.1976-12-311996-08-29Canada
Lasix Special Tablets 500mgTablet500 mgOralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Tab 20mgTablet20 mgOralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Tab 20mgTablet20 mgOralHoechst Canada Inc.1974-12-311996-08-29Canada
Lasix Tab 80mgTablet80 mgOralHoechst Canada Inc.1977-12-311997-08-05Canada
Lasix Tabs 40 mgTablet40 mgOralHoechst Canada Inc.1966-12-311997-08-05Canada
Ntp-furosemideTablet80 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-furosemideTablet20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-furosemideTablet40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-furosemide TabletsTablet20 mgOralNu Pharm Inc2004-12-102012-09-04Canada
Nu-furosemide TabletsTablet40 mgOralNu Pharm Inc2004-03-192012-09-04Canada
Nu-furosemide TabletsTablet80 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-furosemideTablet20 mgOralPharmascience Inc2003-12-10Not applicableCanada
PMS-furosemideTablet40 mgOralPharmascience Inc2003-12-10Not applicableCanada
Teva-furosemideTablet80 mgOralTeva Canada Limited1988-12-31Not applicableCanada
Teva-furosemideTablet20 mgOralTeva Canada Limited1976-12-31Not applicableCanada
Teva-furosemideTablet40 mgOralTeva Canada Limited1976-12-31Not applicableCanada
Uritol TabTablet40 mgOralCarter Horner Corp.1976-12-311996-09-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Furosemide Tab 20mgTablet20 mgOralApotex Inc1977-12-31Not applicableCanada
Apo Furosemide Tab 40mgTablet40 mgOralApotex Inc1976-12-31Not applicableCanada
Apo Furosemide Tab 80mgTablet80 mgOralApotex Inc1986-12-31Not applicableCanada
Diascreen 12-panel Medicated Collection SystemKitIt3 Medical Llc2016-07-27Not applicableUs
FurosemideTablet20 mg/1OralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
FurosemideTablet40 mg/1OralRebel Distirbutors Corp2006-09-18Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health2011-08-22Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousHeritage Pharmaceuticals Inc.2014-09-02Not applicableUs
FurosemideTablet20 mg/1OralClinical Solutions Wholesale, Llc2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralClinical Solutions Wholesale, Llc2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
FurosemideTablet20 mg/1OralTYA Pharmaceuticals2009-01-29Not applicableUs
FurosemideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
FurosemideSolution40 mg/4mLOralPrecision Dose Inc.2012-10-23Not applicableUs
FurosemideTablet20 mg/1OralQualitest Pharmaceuticals2004-03-26Not applicableUs
FurosemideTablet80 mg/1OralA S Medication Solutions Llc2009-01-29Not applicableUs
FurosemideSolution10 mg/mLOralWest Ward Pharmaceuticals Corp.1988-07-12Not applicableUs
FurosemideInjection10 mg/mLIntravenousCardinal Health1990-09-30Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2015-07-13Not applicableUs
FurosemideInjection40 mg/4mLIntramuscular; IntravenousAmneal Biosciences2016-07-25Not applicableUs
FurosemideTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2006-02-01Not applicableUs
FurosemideTablet80 mg/1OralREMEDYREPACK INC.2015-03-16Not applicableUs
FurosemideTablet40 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-07-25Not applicableUs
FurosemideTablet40 mg/1OralDIRECT RX2014-01-01Not applicableUs
FurosemideTablet20 mg/1Oralbryant ranch prepack2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralContract Pharmacy Services Pa2011-02-08Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2010-11-012015-12-29Us
FurosemideTablet40 mg/1OralAidarex Pharmaceuticals LLC2009-01-29Not applicableUs
FurosemideSolution40 mg/5mLOralCardinal Health1987-04-22Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideSolution10 mg/mLOralMorton Grove Pharmaceuticals, Inc.1987-10-02Not applicableUs
FurosemideTablet40 mg/1OralLeading Pharma, Llc2006-02-01Not applicableUs
FurosemideSolution40 mg/5mLOralAtlantic Biologicals Corps1987-04-22Not applicableUs
FurosemideTablet20 mg/1OralProficient Rx LP2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralProficient Rx LP2006-02-01Not applicableUs
FurosemideTablet80 mg/1OralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralREMEDYREPACK INC.2011-10-132016-11-30Us
FurosemideTablet40 mg/1OralMc Kesson Contract Packaging2011-10-11Not applicableUs
FurosemideTablet40 mg/1OralBlenheim Pharmacal, Inc.2013-12-20Not applicableUs
FurosemideTablet40 mg/1OralPhysicians Total Care, Inc.1999-01-04Not applicableUs
FurosemideTablet80 mg/1OralMylan Pharmaceuticals Inc.1986-10-29Not applicableUs
FurosemideTablet40 mg/1OralCardinal Health2011-07-25Not applicableUs
FurosemideTablet40 mg/1OralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
FurosemideInjection10 mg/2mLIntramuscular; IntravenousRebel Distributors Corp1983-11-30Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health1983-11-10Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2015-10-202016-11-23Us
FurosemideTablet40 mg/1OralClinical Solutions Wholesale, Llc2004-03-26Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions2009-01-29Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2011-06-272016-10-28Us
FurosemideTablet80 mg/1OralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralTYA Pharmaceuticals2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
FurosemideTablet40 mg/1OralREMEDYREPACK INC.2010-11-222016-10-13Us
FurosemideTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralQualitest Pharmaceuticals2004-03-26Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions Llc2004-03-26Not applicableUs
FurosemideSolution40 mg/5mLOralWest Ward Pharmaceuticals Corp.1987-04-22Not applicableUs
FurosemideTablet80 mg/1OralCardinal Health1987-08-27Not applicableUs
FurosemideTablet80 mg/1OralREMEDYREPACK INC.2016-02-08Not applicableUs
FurosemideTablet20 mg/1OralIt3 Medical Llc2016-07-26Not applicableUs
FurosemideTablet40 mg/1OralREMEDYREPACK INC.2015-05-15Not applicableUs
FurosemideTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-03-26Not applicableUs
FurosemideTablet80 mg/1OralCardinal Health2010-10-12Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideTablet20 mg/1OralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs
FurosemideTablet80 mg/1OralLeading Pharma, Llc2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralDIRECT RX2014-01-01Not applicableUs
FurosemideTablet20 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2004-10-01Not applicableUs
FurosemideTablet40 mg/1OralContract Pharmacy Services Pa2011-05-01Not applicableUs
FurosemideTablet40 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
FurosemideTablet20 mg/1OralUnit Dose Services2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralMc Kesson Contract Packaging2011-08-29Not applicableUs
FurosemideTablet40 mg/1OralSTAT Rx USA LLC2006-02-01Not applicableUs
FurosemideTablet80 mg/1OralPhysicians Total Care, Inc.1997-03-03Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousHospira, Inc.1999-05-28Not applicableUs
FurosemideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2004-03-26Not applicableUs
FurosemideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralProficient Rx LP2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralReady Meds2004-03-26Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions Llc2004-03-26Not applicableUs
FurosemideTablet40 mg/1Oralbryant ranch prepack2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralMed Vantx, Inc.2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousHeritage Pharmaceuticals Inc.2015-06-26Not applicableUs
FurosemideTablet40 mg/1OralCardinal Health1983-11-10Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideTablet80 mg/1OralClinical Solutions Wholesale2004-03-262016-11-08Us
FurosemideTablet20 mg/1OralPreferred Pharmaceuticals Inc.2016-05-24Not applicableUs
FurosemideTablet80 mg/1OralA S Medication Solutions1986-10-29Not applicableUs
FurosemideTablet40 mg/1OralProficient Rx LP2009-01-29Not applicableUs
FurosemideTablet20 mg/1OralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralREMEDYREPACK INC.2011-09-262016-11-08Us
FurosemideTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
FurosemideTablet80 mg/1OralQualitest Pharmaceuticals2004-03-26Not applicableUs
FurosemideTablet40 mg/1OralA S Medication Solutions Llc2004-03-26Not applicableUs
FurosemideTablet80 mg/1OralWest Ward Pharmaceuticals Corp.1991-03-13Not applicableUs
FurosemideTablet20 mg/1OralCardinal Health1983-11-30Not applicableUs
FurosemideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1991-03-13Not applicableUs
FurosemideTablet20 mg/1OralUnit Dose Services2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralUnit Dose Services2009-01-29Not applicableUs
FurosemideTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-03-26Not applicableUs
FurosemideInjection10 mg/mLIntravenousCardinal Health1990-09-30Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideTablet40 mg/1OralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs
FurosemideInjection100 mg/10mLIntramuscular; IntravenousAmneal Biosciences2016-07-25Not applicableUs
FurosemideTablet80 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2004-10-01Not applicableUs
FurosemideTablet20 mg/1OralRed Pharm Drug Inc.2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
FurosemideSolution40 mg/5mLOralRoxane Laboratories, Inc1987-04-222016-01-06Us
FurosemideTablet20 mg/1OralRebel Distirbutors Corp2006-09-18Not applicableUs
FurosemideInjection10 mg/mLIntravenousPhysicians Total Care, Inc.2005-09-29Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousHospira, Inc.1999-05-28Not applicableUs
FurosemideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2004-03-26Not applicableUs
FurosemideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralClinical Solutions Wholesale, Llc2006-02-01Not applicableUs
FurosemideTablet20 mg/1OralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralReady Meds2004-03-26Not applicableUs
FurosemideTablet40 mg/1OralA S Medication Solutions Llc2004-03-26Not applicableUs
FurosemideTablet80 mg/1Oralbryant ranch prepack1987-08-27Not applicableUs
FurosemideTablet40 mg/1OralMed Vantx, Inc.2012-03-16Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc.2001-03-01Not applicableUs
FurosemideSolution40 mg/5mLOralPrecision Dose Inc.2016-01-28Not applicableUs
FurosemideTablet20 mg/1OralAidarex Pharmaceuticals LLC2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralCardinal Health1986-01-24Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideTablet40 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
FurosemideTablet20 mg/1OralLeading Pharma, Llc2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-25Not applicableUs
FurosemideTablet20 mg/1OralProficient Rx LP2009-01-29Not applicableUs
FurosemideTablet40 mg/1OralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralREMEDYREPACK INC.2011-10-102016-11-29Us
FurosemideTablet20 mg/1OralMc Kesson Contract Packaging2011-10-07Not applicableUs
FurosemideTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-08-30Not applicableUs
FurosemideTablet20 mg/1OralPhysicians Total Care, Inc.2002-11-20Not applicableUs
FurosemideTablet80 mg/1OralWest Ward Pharmaceuticals Corp.1986-01-24Not applicableUs
FurosemideTablet40 mg/1OralCardinal Health1983-11-30Not applicableUs
FurosemideSolution40 mg/5mLOralAtlantic Biologicals Corps1987-04-22Not applicableUs
FurosemideTablet40 mg/1OralUnit Dose Services2006-02-01Not applicableUs
FurosemideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
FurosemideInjection10 mg/mLIntravenousCardinal Health1990-09-30Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
FurosemideInjection, solution10 mg/mLIntravenousREMEDYREPACK INC.2015-03-07Not applicableUs
FurosemideInjection20 mg/2mLIntramuscular; IntravenousAmneal Biosciences2016-07-25Not applicableUs
FurosemideTablet80 mg/1OralMylan Institutional Inc.1996-02-01Not applicableUs
FurosemideTablet20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
FurosemideTablet80 mg/1OralAphena Pharma Solutions Tennessee, Llc1991-03-13Not applicableUs
FurosemideTablet80 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LasixTablet40 mg/1OralPreferred Pharmaceuticals Inc.2016-04-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiurapidMibe Jena
DiurinMylan
DiurmesselBiomep
EutensinSanofi
FrumexNot Available
FrusenexNot Available
FrusolRosemont
Furo-PurenActavis
SegurilSanofi
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7LXU5N7ZO5
CAS number54-31-9
WeightAverage: 330.744
Monoisotopic: 330.007719869
Chemical FormulaC12H11ClN2O5S
InChI KeyZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
Structured Indications
PharmacodynamicsFurosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.
Mechanism of actionFurosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Carbonic anhydrase 2ProteinunknownNot AvailableHumanP00918 details
Related Articles
Absorption60% absorbed in patients with normal renal function
Volume of distributionNot Available
Protein binding95% bound to plasma proteins
Metabolism

Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.

SubstrateEnzymesProduct
Furosemide
Not Available
4-chloro-5-sulfamoylanthranilic acidDetails
Route of eliminationFurosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.
Half life2 hours
ClearanceNot Available
ToxicityProfound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Furosemide Action PathwayDrug actionSMP00115
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Furosemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Furosemide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the diuretic activities of Furosemide.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.Withdrawn
AcetovanilloneAcetovanillone may decrease the diuretic activities of Furosemide.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Furosemide.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Furosemide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Furosemide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Furosemide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide.Approved, Illicit
AliskirenThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Furosemide is combined with Allopurinol.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Furosemide.Experimental, Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Furosemide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Furosemide is combined with Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Furosemide.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Furosemide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Furosemide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Furosemide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Furosemide is combined with Amphotericin B.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Furosemide is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Furosemide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Furosemide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Furosemide.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Furosemide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Furosemide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Furosemide.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Arbekacin.Approved
ArbutamineArbutamine may increase the hypokalemic activities of Furosemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Furosemide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Furosemide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Furosemide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Furosemide.Approved
Atracurium besylateFurosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Furosemide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Furosemide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Furosemide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Furosemide.Investigational
BalsalazideBalsalazide may decrease the diuretic activities of Furosemide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Furosemide.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Furosemide.Experimental
BarbitalBarbital may increase the hypotensive activities of Furosemide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Furosemide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Furosemide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Furosemide.Approved
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Furosemide.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Furosemide is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Furosemide.Approved
Betulinic AcidBetulinic Acid may decrease the diuretic activities of Furosemide.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Furosemide.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Furosemide is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Furosemide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.Approved
BromfenacBromfenac may decrease the diuretic activities of Furosemide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Furosemide is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the diuretic activities of Furosemide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Furosemide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Furosemide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Furosemide is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Furosemide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Candesartan.Approved
CandoxatrilFurosemide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Furosemide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Furosemide.Illicit, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Furosemide is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the diuretic activities of Furosemide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Furosemide.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloroquineChloroquine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Furosemide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Furosemide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilnidipine.Approved
Cisatracurium besylateFurosemide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinFurosemide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Furosemide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Furosemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Furosemide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.Approved
ClonixinClonixin may decrease the diuretic activities of Furosemide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Furosemide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Furosemide is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Furosemide.Approved
CurcuminCurcumin may decrease the diuretic activities of Furosemide.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the diuretic activities of Furosemide.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.Approved
DaunorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Daunorubicin.Approved
DecamethoniumFurosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Furosemide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Furosemide.Investigational
dersalazinedersalazine may decrease the diuretic activities of Furosemide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Furosemide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.Approved
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Furosemide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Furosemide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Furosemide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Furosemide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furosemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furosemide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Furosemide.Approved
DiclofenacDiclofenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Diclofenamide.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Furosemide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Furosemide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Furosemide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Furosemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furosemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dihydrostreptomycin.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Furosemide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Furosemide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Furosemide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Furosemide.Approved
DofetilideFurosemide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidFurosemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideFurosemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Furosemide.Investigational
DroxicamDroxicam may decrease the diuretic activities of Furosemide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Furosemide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Furosemide.Approved
DuloxetineFurosemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the diuretic activities of Furosemide.Investigational
E6201E6201 may decrease the diuretic activities of Furosemide.Investigational
EbselenEbselen may decrease the diuretic activities of Furosemide.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Furosemide.Approved, Vet Approved
EnalaprilatFurosemide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Furosemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Furosemide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Furosemide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Furosemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Furosemide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Furosemide.Approved
EstroneEstrone may increase the hypokalemic activities of Furosemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Furosemide.Approved
Etacrynic acidFurosemide may increase the ototoxic activities of Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Furosemide.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furosemide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Furosemide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Furosemide.Approved
EtoricoxibEtoricoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Furosemide.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Furosemide.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Furosemide.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Furosemide.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the diuretic activities of Furosemide.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Furosemide is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Furosemide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Furosemide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the diuretic activities of Furosemide.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Furosemide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Furosemide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Furosemide.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Furosemide.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Furosemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Furosemide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Furosemide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Furosemide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Furosemide.Approved
FormestaneFormestane may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Furosemide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Furosemide.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Furosemide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Furosemide is combined with Framycetin.Approved
Gallamine TriethiodideFurosemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Furosemide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Furosemide is combined with GENTAMICIN C1A.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Furosemide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Furosemide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Furosemide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Furosemide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Furosemide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Furosemide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Furosemide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Furosemide.Approved, Illicit
HexobarbitalHexobarbital may increase the hypotensive activities of Furosemide.Approved
HigenamineHigenamine may decrease the diuretic activities of Furosemide.Investigational
HMPL-004HMPL-004 may decrease the diuretic activities of Furosemide.Investigational
HyaluronidaseThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Furosemide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Furosemide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Furosemide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Furosemide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Furosemide is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Furosemide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Furosemide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.Approved
IndomethacinIndomethacin may decrease the diuretic activities of Furosemide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Furosemide.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Furosemide is combined with Indoramin.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Furosemide is combined with INNO-206.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Furosemide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Furosemide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Furosemide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Furosemide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Furosemide is combined with Isocarboxazid.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Furosemide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Furosemide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Furosemide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Furosemide.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Furosemide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Furosemide.Investigational
IvabradineFurosemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Kanamycin.Approved, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Furosemide.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furosemide.Approved
KetoprofenKetoprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Furosemide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Lacidipine.Approved
LeflunomideLeflunomide may decrease the diuretic activities of Furosemide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Furosemide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Furosemide is combined with Levobupivacaine.Approved
LevodopaFurosemide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furosemide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Furosemide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Furosemide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Furosemide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Furosemide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Furosemide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Furosemide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the diuretic activities of Furosemide.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Furosemide.Approved
LumiracoxibLumiracoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Furosemide.Approved
MannitolThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the diuretic activities of Furosemide.Approved
ME-609ME-609 may increase the hypokalemic activities of Furosemide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Furosemide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Furosemide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Furosemide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
MesalazineMesalazine may decrease the diuretic activities of Furosemide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Furosemide.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Furosemide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Furosemide.Approved
MethotrexateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Furosemide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Furosemide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.Approved
MetocurineFurosemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideFurosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Furosemide.Approved, Investigational
MetrizamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metrizamide.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Furosemide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Furosemide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Furosemide.Approved, Investigational
MivacuriumFurosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Furosemide.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Furosemide.Approved
MometasoneMometasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Furosemide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Furosemide.Approved
NabiloneThe risk or severity of adverse effects can be increased when Furosemide is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the diuretic activities of Furosemide.Approved
NadololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.Approved
NafamostatNafamostat may decrease the diuretic activities of Furosemide.Investigational
NaftifineNaftifine may decrease the diuretic activities of Furosemide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.Approved
NaproxenNaproxen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Furosemide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Furosemide.Investigational
NCX 4016NCX 4016 may decrease the diuretic activities of Furosemide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinFurosemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Furosemide.Approved
NesiritideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Netilmicin.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.Approved
NicorandilNicorandil may increase the hypotensive activities of Furosemide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Furosemide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the diuretic activities of Furosemide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the diuretic activities of Furosemide.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Furosemide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Furosemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Furosemide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Furosemide is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Furosemide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Furosemide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Furosemide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Furosemide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Furosemide.Approved
OmapatrilatFurosemide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Furosemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Furosemide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Furosemide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Furosemide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Furosemide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Furosemide is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Furosemide.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Furosemide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumFurosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Furosemide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Furosemide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Furosemide is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Furosemide.Approved, Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Furosemide.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Furosemide.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Furosemide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Pipamperone.Approved
PipecuroniumFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Furosemide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Furosemide.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Furosemide.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Furosemide.Approved, Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Plicamycin.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Furosemide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Furosemide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Furosemide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Furosemide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Furosemide.Experimental
PrimidonePrimidone may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Furosemide.Approved
PropacetamolPropacetamol may decrease the diuretic activities of Furosemide.Approved
PropofolThe risk or severity of adverse effects can be increased when Furosemide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.Approved, Investigational
PTC299PTC299 may decrease the diuretic activities of Furosemide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Puromycin.Experimental
PyrantelFurosemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide.Approved
RapacuroniumFurosemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Furosemide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Furosemide.Approved, Investigational
RescinnamineFurosemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Furosemide.Approved
ResveratrolResveratrol may decrease the diuretic activities of Furosemide.Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.Approved
RimexoloneRimexolone may increase the hypokalemic activities of Furosemide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Furosemide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Furosemide.Approved
RocuroniumFurosemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Furosemide.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Furosemide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Furosemide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Furosemide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Furosemide is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Furosemide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Furosemide.Approved
SalsalateSalsalate may decrease the diuretic activities of Furosemide.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Furosemide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Furosemide is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the diuretic activities of Furosemide.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Furosemide is combined with Sevoflurane.Approved, Vet Approved
SisomicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Sisomicin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Furosemide is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.Approved
SP1049CThe risk or severity of adverse effects can be increased when Furosemide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Spectinomycin.Approved, Vet Approved
SpiraprilFurosemide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Furosemide.Approved
SRT501SRT501 may decrease the diuretic activities of Furosemide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptokinase.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptozocin.Approved
SuccinylcholineFurosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Furosemide.Approved
SulindacSulindac may decrease the diuretic activities of Furosemide.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Furosemide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved
SuprofenSuprofen may decrease the diuretic activities of Furosemide.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Furosemide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.Approved, Investigational
TemocaprilFurosemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the diuretic activities of Furosemide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Furosemide.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Furosemide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Furosemide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Furosemide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Furosemide.Investigational
ThiopentalThiopental may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Furosemide is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Furosemide.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Furosemide.Approved
TinoridineTinoridine may decrease the diuretic activities of Furosemide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Furosemide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.Approved
TobramycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Tobramycin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Furosemide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Furosemide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Furosemide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Furosemide.Approved
TolmetinTolmetin may decrease the diuretic activities of Furosemide.Approved
TopiramateFurosemide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide.Approved
TranilastTranilast may decrease the diuretic activities of Furosemide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Furosemide is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Furosemide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Furosemide.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Furosemide.Withdrawn
TubocurarineFurosemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Furosemide.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.Approved, Investigational
VecuroniumFurosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Furosemide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Furosemide.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the diuretic activities of Furosemide.Approved
ZileutonZileuton may decrease the diuretic activities of Furosemide.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the diuretic activities of Furosemide.Withdrawn
ZorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Zorubicin.Experimental
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food to reduce irritation.
References
Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, “Process for the preparation of furosemide.” U.S. Patent US5739361, issued June, 1971.

US5739361
General References
  1. Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [PubMed:15311369 ]
  2. Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [PubMed:7870036 ]
  3. Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [PubMed:8642407 ]
  4. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [PubMed:8794909 ]
External Links
ATC CodesC03EB01C03CB01C03CA01
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (462 KB)
MSDSDownload (74.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier-0.8833
Caco-2 permeable-0.6436
P-glycoprotein substrateNon-substrate0.8775
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.6878
CYP450 2D6 substrateNon-substrate0.8351
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9602
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6469
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.1362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9342
hERG inhibition (predictor II)Non-inhibitor0.8525
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Organon usa inc
  • Smith and nephew solopak div smith and nephew
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Wockhardt ltd
  • Wyeth ayerst laboratories
  • Sanofi aventis us llc
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Dava pharmaceuticals inc
  • Excellium pharmaceutical inc
  • International medication systems ltd
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kalapharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Vintage pharmaceuticals inc
  • County line pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Kit
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous100 mg/10mL
InjectionIntramuscular; Intravenous20 mg/2mL
InjectionIntramuscular; Intravenous40 mg/4mL
InjectionIntravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
SolutionOral10 mg/mL
SolutionOral40 mg/5mL
SolutionOral40 mg/4mL
LiquidIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous10 mg
SolutionIntravenous10 mg
LiquidIntravenous10 mg
TabletOral80 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
LiquidOral10 mg
SolutionOral10 mg
LiquidIntramuscular; Intravenous20 mg
TabletOral500 mg
TabletOral20 mg
TabletOral40 mg
Prices
Unit descriptionCostUnit
Hydro 40 40% Foam 150 gm Can182.52USD can
Hydro 40 40% Foam 70 gm Can148.99USD can
Furosemide 10 mg/ml Solution 60ml Bottle17.99USD bottle
Furosemide 10 mg/ml Solution 120ml Bottle15.98USD bottle
Furosemide powder3.51USD g
Lasix Special 500 mg Tablet3.25USD tablet
Urex 1 gm tablet2.47USD tablet
Furosemide 10 mg/ml cartrg1.45USD ml
Lasix 80 mg tablet1.0USD tablet
Furosemide 10 mg/ml Solution0.9USD ml
Furosemide 10 mg/ml0.75USD ml
Lasix 40 mg tablet0.53USD tablet
Furosemide 80 mg tablet0.45USD tablet
Lasix 20 mg tablet0.42USD tablet
Lasix 10 mg/ml Solution0.3USD ml
CVS Pharmacy diuretic 50 mg softgel0.17USD softgel capsule
Furosemide 40 mg tablet0.16USD tablet
Furosemide 20 mg tablet0.14USD tablet
Apo-Furosemide 80 mg Tablet0.13USD tablet
Novo-Semide 80 mg Tablet0.13USD tablet
Nat herbal diuretic tablet sa0.1USD tablet
Apo-Furosemide 40 mg Tablet0.07USD tablet
Natural herbal diuretic tablet0.07USD tablet
Novo-Semide 40 mg Tablet0.07USD tablet
Apo-Furosemide 20 mg Tablet0.05USD tablet
Novo-Semide 20 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206U.S. Patent 3,058,882.
water solubility73.1 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.03SANGSTER (1993)
logS-3.66ADME Research, USCD
Caco2 permeability-6.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP2.71ALOGPS
logP1.75ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)4.25ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area122.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.47 m3·mol-1ChemAxon
Polarizability30.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-03dr-0090000000-da505a3f09285d049f34View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-0f89-2190000000-53c91100e89c81f0fa30View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-01ox-9660000000-83d8486cbca0dd3487c9View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Aminobenzenesulfonamide
  • Halobenzoic acid
  • 4-halobenzoic acid
  • 4-halobenzoic acid or derivatives
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Furan
  • Oxacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [PubMed:10653443 ]
  2. Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [PubMed:1092541 ]
  3. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:
PGD
Uniprot ID:
P52209
Molecular Weight:
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [PubMed:12897087 ]
  2. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087 ]
  3. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961 ]
  4. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23